1. Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care

2. The Royal College of Ophthalmologists (RCOphth). The Way Forward. Options to Help Meet Demand for the Current and Future Care of Patients with Eye Disease —age-Related Macular Degeneration and Diabetic Retinopathy. London: RCOphth; 2017. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2015/10/RCOphth-The-Way-Forward-AMD-300117.pdf. Accessed January 2019.

3. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome

4. National Institute of Health and Clinical Excellence (NICE). Ranibizumab and Pegaptanib for the Treatment of Age-Related Macular Degeneration. NICE Technology Appraisal Guidance TA155. London: NICE; 2008. Available from: www.nice.org.uk/guidance/ta155/resources/ranibizumab-and-pegaptanib-for-the-treatment-of-agerelated-macular-degeneration-pdf-82598316423109. Accessed January 2019.

5. Scottish Medicines Consortium (SMC). Ranibizumab 10mg/Ml Solution for Intravitreal Injection (Lucentis®). SMC No. (381/07). Glasgow: SMC; 2007. Available from: www.scottishmedicines.org.uk/media/2217/ranibizumab_10mgmlsolution_intravitrealinjection_lucentis_38107.pdf. Accessed January 2019.